SP Angel Healthcare Conditions- 28-04-2021

Morning Note – 22 March 2024

Gym Group - The power of marginal gains

Gym Group has accompanied confirmation of FY23 profit resilience and continued buoyancy (like-for-like revenue up 12% in the first two months of 2024) with a clear commitment ‘to accelerate, not reinvent the wheel.’ The latter is telling with new senior management endorsing Gym Group’s sweet spot as a low-cost operator in the long-term growth market of health and fitness. Its confidence in material scope for enhanced pricing and member acquisition and retention is complemented by expansion targe

Avacta Group - AACR update

As pre-announced, Avacta has presented the results of the 3-weekly P1 Arm 1 study of its AVA6000 lead clinical asset, based on the pre|CISION™ drug development platform at the American Association for Cancer Research's annual general meeting. The update does not cover progress on the ongoing 2-weekly dosing study which is underway, and Avacta confirmed current guidance on timing including being on track to begin the dose expansion study in 2H24. There are compelling updates on the progress repor

Anexo Group (ANX LN) - Controlled growth, net debt reduced

H1 performance has delivered strong revenue and profit growth, with the careful management of vehicle volumes and increased cash collections, resulting in a significant reduction in net debt. FY23 outlook is unchanged, underpinned by the strong market opportunity across divisions.

Strong trading and investing for growth

Year-end trading update